1Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA
2Department of Pharmacology, Faculty of Medicine, Tanta University, Tanta, Egypt
3Final year student, College of Pharmacy, Taif University, Taif, KSA
Journal of Cancer Research and Treatment.
2016,
Vol. 4 No. 4, 55-60
DOI: 10.12691/jcrt-4-4-1
Copyright © 2016 Science and Education PublishingCite this paper: Ahmed M. Kabel, Abrar A. Al-joaid, Afnan A. Al-ghamdi, Aseel A. Al-joaid, Wejdan S. Al-zaidi. Hepatocellular Carcinoma: A Focus on the New Lines of Management.
Journal of Cancer Research and Treatment. 2016; 4(4):55-60. doi: 10.12691/jcrt-4-4-1.
Correspondence to: Ahmed M. Kabel, Department of Clinical Pharmacy, College of Pharmacy, Taif University, Taif, KSA. Email:
drakabel@gmail.comAbstract
Hepatocellular carcinomas (HCCs) are aggressive tumors with a high dissemination rate. Diagnosis of HCC depends on physical examination, computed tomography, magnetic resonance imaging and biopsy results. An early diagnosis of these tumors is of great importance in order to offer the possibility of curative treatment. HCC is relatively insensitive to systemic therapy, radiotherapy or surgery and this usually depends on the stage of the disease. Diagnosis and treatment of HCC has witnessed many major changes and challenges in the past years. New alternative lines of treatment of HCC were developed to attack the tumor at the molecular level to improve the prognosis and achieve better results. These include check-point inhibitor therapy, molecular targeted therapy and angiogenesis inhibitors.
Keywords